
Antengene Corporation Ltd
HKEX:6996

Antengene Corporation Ltd
Other Equity
Antengene Corporation Ltd
Other Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Other Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
Antengene Corporation Ltd
HKEX:6996
|
Other Equity
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Other Equity
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Other Equity
ÂĄ127.7m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-3%
|
|
![]() |
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Other Equity
ÂĄ17m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Other Equity
ÂĄ1.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Other Equity
ÂĄ836.1k
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
Antengene Corporation Ltd
Glance View
Antengene Corp. Ltd. operates as clinical-stage Asia-Pacific biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-20. The firm is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company’s products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The firm mainly conducts its business in Asia-Pacific.
